# Response to Kuvan® in Subjects With Phenylketonuria (PKU) in a 4 Weeks Testing Period

> **NCT01082328** · PHASE4 · COMPLETED · sponsor: **Merck KGaA, Darmstadt, Germany** · enrollment: 59 (actual)

## Conditions studied

- Phenylketonuria

## Interventions

- **DRUG:** Kuvan®

## Key facts

- **NCT ID:** NCT01082328
- **Lead sponsor:** Merck KGaA, Darmstadt, Germany
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-05
- **Primary completion:** 2012-05
- **Final completion:** 2012-05
- **Target enrollment:** 59 (ACTUAL)
- **Last updated:** 2014-02-27

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01082328

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01082328, "Response to Kuvan® in Subjects With Phenylketonuria (PKU) in a 4 Weeks Testing Period". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT01082328. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*